Acrivon director granted option on 20,275 shares

Acrivon Therapeutics director Derek DiRocco was granted a stock option covering 20,275 shares of common stock at an exercise price of $1.52 per share, expiring on June 16, 2036.

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Form Type

Rhea-AI Filing Summary

Acrivon Therapeutics director Derek DiRocco was granted a stock option covering 20,275 shares of common stock at an exercise price of $1.52 per share, expiring on June 16, 2036. The option vests immediately before Acrivon’s next annual stockholder meeting, subject to his continuous service.

The option is held for the benefit of RA Capital Healthcare Fund, L.P. and RA Capital Nexus Fund II, L.P. Any net cash or stock from exercise must be turned over to RA Capital Management, L.P., and DiRocco disclaims beneficial ownership of the option and underlying shares.

Insider Trade Summary

Grant/Award: 20,275 shares

Grant/Award 1 txn

Insider DiRocco Derek

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy)	20,275	$0.00	$0.00

Holdings After Transaction: Stock Option (Right to Buy) — 20,275 contracts (Direct)

Footnotes (2)

F1. The shares subject to the option shall vest on the date immediately preceding the date of the Issuer's next annual meeting of stockholders, subject to the Reporting Person's continuous service through the applicable vesting date.
F2. Under the Reporting Person's arrangement with RA Capital Management, L.P. (the "Adviser"), the Reporting Person holds the stock option for the benefit of RA Capital Healthcare Fund, L.P. (the "Fund") and RA Capital Nexus Fund II, L.P. (the "Nexus Fund II"). The Reporting Person is obligated to turn over to the Adviser any net cash or stock received upon exercise of the stock option, which will offset advisory fees owed by the Fund and the Nexus Fund II to the Adviser. The Reporting Person therefore disclaims beneficial ownership of the stock option and underlying Common Stock.

Key Figures

Option size: 20,275 shares Exercise price: $1.52 per share Expiration date: June 16, 2036 +2 more

5 metrics

Option size 20,275 shares Stock option covering Acrivon common stock

Exercise price $1.52 per share Conversion or exercise price of the option

Expiration date June 16, 2036 Option expiration for the stock option grant

Shares after grant 20,275 derivative shares Total derivative holdings following the transaction

Grant price $0.00 per option Compensation grant with no purchase price paid at grant

Key Terms

Stock Option (Right to Buy), beneficial ownership, continuous service, underlying Common Stock

4 terms

Stock Option (Right to Buy) financial

"security_title: "Stock Option (Right to Buy)""

beneficial ownership financial

"The Reporting Person therefore disclaims beneficial ownership of the stock option and underlying Common Stock."

Beneficial ownership means the person or entity that actually enjoys the benefits of owning shares or other assets — such as receiving dividends, voting rights, or price gains — even if the legal title is held in another name. For investors it matters because knowing who truly controls and profits from a company reveals who can influence decisions, exposes potential conflicts of interest or hidden concentration of power, and affects transparency and risk in the stock.

continuous service financial

"subject to the Reporting Person's continuous service through the applicable vesting date."

underlying Common Stock financial

"stock option and underlying Common Stock."

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Acrivon Therapeutics (ACRV) report in this Form 4?

Acrivon Therapeutics reported a grant of a stock option for 20,275 shares of common stock at a $1.52 exercise price to director Derek DiRocco. The option is compensation-related and not an open-market share purchase or sale.

How many Acrivon Therapeutics (ACRV) shares are covered by the new option?

The new stock option covers 20,275 shares of Acrivon Therapeutics common stock. This entire amount is reflected as the director’s derivative holdings following the transaction in the Form 4 data.

What is the exercise price and expiration date of the ACRV option grant?

The stock option has an exercise price of $1.52 per share and expires on June 16, 2036. These terms define the cost and time window for exercising the right to buy Acrivon Therapeutics common shares.

When does the new Acrivon Therapeutics (ACRV) stock option vest?

The option will vest on the date immediately preceding Acrivon Therapeutics’ next annual meeting of stockholders. Vesting is conditional on Derek DiRocco’s continuous service with the company through that vesting date, as disclosed in the footnote.

Who ultimately benefits from this Acrivon Therapeutics (ACRV) option grant?

Under an arrangement with RA Capital Management, L.P., the option is held for RA Capital Healthcare Fund, L.P. and RA Capital Nexus Fund II, L.P. Any net cash or stock from exercise offsets advisory fees, and DiRocco disclaims beneficial ownership.

Is this Acrivon Therapeutics (ACRV) Form 4 an open-market trade?

No. The Form 4 reports a grant of a stock option as compensation, not an open-market purchase or sale of existing Acrivon shares. The transaction is categorized as a derivative grant/award acquisition in the filing data.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Accepted by SEC EDGAR 06/22/2026 - 04:09 PM EDT

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

DiRocco Derek

(Last)

(First)

(Middle)

C/O ACRIVON THERAPEUTICS, INC.

480 ARSENAL WAY, SUITE 100

(Street)

WATERTOWN

MASSACHUSETTS

02472

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Acrivon Therapeutics, Inc. [ ACRV ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
	Officer (give title below)	Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/17/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Stock Option (Right to Buy)	$1.52	06/17/2026		A		20,275		⁽¹⁾	06/16/2036	Common Stock	20,275	$0	20,275	D⁽²⁾

Explanation of Responses:

1. The shares subject to the option shall vest on the date immediately preceding the date of the Issuer's next annual meeting of stockholders, subject to the Reporting Person's continuous service through the applicable vesting date.

2. Under the Reporting Person's arrangement with RA Capital Management, L.P. (the "Adviser"), the Reporting Person holds the stock option for the benefit of RA Capital Healthcare Fund, L.P. (the "Fund") and RA Capital Nexus Fund II, L.P. (the "Nexus Fund II"). The Reporting Person is obligated to turn over to the Adviser any net cash or stock received upon exercise of the stock option, which will offset advisory fees owed by the Fund and the Nexus Fund II to the Adviser. The Reporting Person therefore disclaims beneficial ownership of the stock option and underlying Common Stock.

	/s/ Adam D. Levy, Attorney-in-Fact	06/22/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR